1. Pink Sheet

Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?

 
• By Michael McCaughan

The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet